Cephalalgia

Papers
(The H4-Index of Cephalalgia is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution162
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial88
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention79
Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia71
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study70
Isolated intracranial hypertension associated with COVID-1970
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine70
Migraine therapeutics differentially modulate the CGRP pathway67
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis60
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients59
Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients58
The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study52
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis48
Prevalence of neck pain in migraine: A systematic review and meta-analysis46
Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study46
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials46
Clinical, oculographic, and vestibular test characteristics of vestibular migraine45
Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study45
I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children44
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study43
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis43
Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study43
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database41
A systematic review of treatment for patients with burning mouth syndrome41
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study40
Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: Lessons from the 1890 Russian/Asiatic flu39
The role of cytokines in migraine: A systematic review39
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study37
E-diary use in clinical headache practice: A prospective observational study36
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial36
CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine36
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study36
Incidence of spontaneous intracranial hypotension in a community: Beverly Hills, California, 2006–202035
Diagnosis and treatment of idiopathic intracranial hypertension34
0.060084104537964